Patients with hematologic malignancies are particularly vulnerable to infections due to underlying humoral and cellular immune dysfunction, cytotoxic chemotherapy regimens, advanced age, and the presence of comorbid conditions. Infection from severe acute respiratory syndrome coronavirus 2, the causative agent of the COVID-19 pandemic, has become a leading cause of death globally and has disproportionally affected this high-risk population. Here, we review the cumulative evidence demonstrating worse outcomes for patients with hematologic malignancies when compared to patients with solid tumors and the general population. We examine risk factors shared with the general population (age, sex, comorbid conditions, and race) and those that are cancer-specific (cytotoxic chemotherapy, progressive disease, and cancer type), all of which confer an increased risk of severe COVID-19. Despite the historical exclusion of cancer patients from COVID-19 therapy trials, we review the emerging evidence that patients with hematologic malignancies benefit from specific treatments such as convalescent plasma. Although COVID-19 vaccines are significantly less effective in this patient population, encouraging results are observed in a subset of these patients after receiving a booster dose.

1.
WHO Coronavirus (COVID-19) Dashboard
.
WHO coronavirus (COVID-19) dashboard with vaccination data [Internet]
.
WHO
;
2022
[cited 2022 Jan 24]. Available from: https://covid19.who.int/.
2.
Liang
W
,
Guan
W
,
Chen
R
,
Wang
W
,
Li
J
,
Xu
K
,
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
.
Lancet Oncol
.
2020
;
21
(
3
):
335
7
.
3.
Zhang
L
,
Zhu
F
,
Xie
L
,
Wang
C
,
Wang
J
,
Chen
R
,
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
.
Ann Oncol
.
2020
;
31
(
7
):
894
901
.
4.
Dai
M
,
Liu
D
,
Liu
M
,
Zhou
F
,
Li
G
,
Chen
Z
,
Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak
.
Cancer Discov
.
2020
;
10
(
6
):
783
91
.
5.
Mehta
V
,
Goel
S
,
Kabarriti
R
,
Cole
D
,
Goldfinger
M
,
Acuna-Villaorduna
A
,
Case fatality rate of cancer patients with COVID-19 in a New York hospital system
.
Cancer Discov
.
2020
;
10
(
7
):
935
41
.
6.
Passamonti
F
,
Cattaneo
C
,
Arcaini
L
,
Bruna
R
,
Cavo
M
,
Merli
F
,
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
.
Lancet Haematol
.
2020
;
7
(
10
):
e737
45
.
7.
García-Suárez
J
,
de la Cruz
J
,
Cedillo
Á
,
Llamas
P
,
Duarte
R
,
Jiménez-Yuste
V
,
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
.
J Hematol Oncol
.
2020
;
13
(
1
):
133
.
8.
Rubinstein
SM
,
Warner
JL
.
COVID-19 and haematological malignancy: navigating a narrow strait
.
Lancet Haematol
.
2020
;
7
(
10
):
e701
3
. .
9.
Desai
A
,
Mohammed
TJ
,
Duma
N
,
Garassino
MC
,
Hicks
LK
,
Kuderer
NM
,
COVID-19 and cancer: a review of the registry-based pandemic response
.
JAMA Oncol
.
2021
;
7
(
12
):
1882
90
. .
10.
Kuderer
NM
,
Choueiri
TK
,
Shah
DP
,
Shyr
Y
,
Rubinstein
SM
,
Rivera
DR
,
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
.
Lancet
.
2020
;
395
(
10241
):
1907
18
.
11.
Desai
A
,
Warner
J
,
Kuderer
N
,
Thompson
M
,
Painter
C
,
Lyman
G
,
Crowdsourcing a crisis response for COVID-19 in oncology
.
Nat Cancer
.
2020
;
1
(
5
):
473
6
.
12.
Grivas
P
,
Khaki
AR
,
Wise-Draper
TM
,
French
B
,
Hennessy
C
,
Hsu
CY
,
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and cancer consortium
.
Ann Oncol
.
2021
;
32
(
6
):
787
800
.
13.
Lee
LYW
,
Cazier
JB
,
Starkey
T
,
Briggs
SEW
,
Arnold
R
,
Bisht
V
,
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
.
Lancet Oncol
.
2020
;
21
(
10
):
1309
16
.
14.
Pinato
DJ
,
Zambelli
A
,
Aguilar-Company
J
,
Bower
M
,
Sng
CCT
,
Salazar
R
,
Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer
.
Cancer Discov
.
2020
;
10
(
10
):
1465
74
.
15.
Jee
J
,
Foote
MB
,
Lumish
M
,
Stonestrom
AJ
,
Wills
B
,
Narendra
V
,
Chemotherapy and COVID-19 outcomes in patients with cancer
.
J Clin Oncol
.
2020
;
38
(
30
):
3538
46
.
16.
Pagano
L
,
Salmanton-García
J
,
Marchesi
F
,
Busca
A
,
Corradini
P
,
Hoenigl
M
,
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
.
J Hematol Oncol
.
2021
;
14
(
1
):
168
.
17.
ASH RC COVID-19 [Internet]. [cited 2021 Oct 21]. Available from: https://www.ashresearchcollaborative.org/s/covid-19-registry.
18.
Wood
WA
,
Neuberg
DS
,
Thompson
JC
,
Tallman
MS
,
Sekeres
MA
,
Sehn
LH
,
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH research collaborative data hub
.
Blood Adv
.
2020
;
4
(
23
):
5966
75
.
19.
Nadkarni
AR
,
Vijayakumaran
SC
,
Gupta
S
,
Divatia
JV
.
Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: a systematic review and meta-analysis
.
JCO Glob Oncol
.
2021
;
7
(
7
):
1286
305
. .
20.
Regalado-Artamendi
I
,
Jiménez-Ubieto
A
,
Hernández-Rivas
,
Navarro
B
,
Núñez
L
,
Alaez
C
,
Risk factors and mortality of COVID-19 in patients with lymphoma: a Multicenter Study
.
Hemasphere
.
2021
;
5
(
3
):
e538
.
21.
Vijenthira
A
,
Gong
IY
,
Fox
TA
,
Booth
S
,
Cook
G
,
Fattizzo
B
,
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
.
Blood
.
2020
;
136
(
25
):
2881
92
.
22.
Peckham
H
,
de Gruijter
NM
,
Raine
C
,
Radziszewska
A
,
Ciurtin
C
,
Wedderburn
LR
,
Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
.
Nat Commun
.
2020
;
11
(
1
):
6317
.
23.
Piñana
JL
,
Martino
R
,
García-García
I
,
Parody
R
,
Morales
MD
,
Benzo
G
,
Risk factors and outcome of COVID-19 in patients with hematological malignancies
.
Exp Hematol Oncol
.
2020
;
9
(
1
):
21
.
24.
Tian
J
,
Yuan
X
,
Xiao
J
,
Zhong
Q
,
Yang
C
,
Liu
B
,
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
.
Lancet Oncol
.
2020
;
21
(
7
):
893
903
.
25.
Albiges
L
,
Foulon
S
,
Bayle
A
,
Gachot
B
,
Pommeret
F
,
Willekens
C
,
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
.
Nat Cancer
.
2020
;
1
(
10
):
965
75
.
26.
Chari
A
,
Samur
MK
,
Martinez-Lopez
J
,
Cook
G
,
Biran
N
,
Yong
K
,
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
.
Blood
.
2020
;
136
(
26
):
3033
40
.
27.
Mato
AR
,
Roeker
LE
,
Lamanna
N
,
Allan
JN
,
Leslie
L
,
Pagel
JM
,
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
.
Blood
.
2020
;
136
(
10
):
1134
43
.
28.
Mehta
P
,
McAuley
DF
,
Brown
M
,
Sanchez
E
,
Tattersall
RS
,
Manson
JJ
,
COVID-19: consider cytokine storm syndromes and immunosuppression
.
Lancet
.
2020
;
395
(
10229
):
1033
4
.
29.
Valle
DMD
,
Kim-Schulze
S
,
Huang
HH
,
Beckmann
ND
,
Nirenberg
S
,
Wang
B
,
An inflammatory cytokine signature predicts COVID-19 severity and survival
.
Nat Med
.
2020
;
26
(
10
):
1636
43
.
30.
Wynants
L
,
Calster
BV
,
Collins
GS
,
Riley
RD
,
Heinze
G
,
Schuit
E
,
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
.
BMJ
.
2020
;
369
:
m1328
.
31.
D’Aiello
A
,
Zareef
S
,
Pradhan
K
,
Lombardo
A
,
Khatun
F
,
Mustafa
J
,
Older age and increased neutrophil-to-lymphocyte ratio (NLR) are predictors of mortality in a multiethnic urban cohort of hematologic neoplasms and COVID-19 patients
.
Blood
.
2020
;
136
(
Supplement 1
):
34
5
.
32.
Yancy
CW
.
COVID-19 and African Americans
.
JAMA
.
2020
;
323
(
19
):
1891
2
. .
33.
Chowkwanyun
M
,
Reed
AL
 Jr
.
Racial health disparities and covid-19 – caution and context
.
N Engl J Med
.
2020
;
383
(
3
):
201
3
.
34.
Mackey
K
,
Ayers
CK
,
Kondo
KK
,
Saha
S
,
Advani
SM
,
Young
S
,
Racial and ethnic disparities in COVID-19: related infections, hospitalizations, and deaths: a systematic review
.
Ann Intern Med
.
2021
;
174
(
3
):
362
73
.
35.
Schmidt
AL
,
Bakouny
Z
,
Bhalla
S
,
Steinharter
JA
,
Tremblay
DA
,
Awad
MM
,
Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer Outcomes Study
.
Cancer Cell
.
2020
;
38
(
6
):
769
70
.
36.
Rivera
DR
,
Peters
S
,
Panagiotou
OA
,
Shah
DP
,
Kuderer
NM
,
Hsu
CY
,
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer consortium (CCC19) Cohort Study
.
Cancer Discov
.
2020
;
10
(
10
):
1514
27
.
37.
Hultcrantz
M
,
Richter
J
,
Rosenbaum
CA
,
Patel
D
,
Smith
EL
,
Korde
N
,
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
.
Blood Cancer Discov
.
2020
;
1
(
3
):
234
43
.
38.
Bakouny
Z
,
Hawley
JE
,
Choueiri
TK
,
Peters
S
,
Rini
BI
,
Warner
JL
,
COVID-19 and cancer: current challenges and perspectives
.
Cancer Cell
.
2020
;
38
(
5
):
629
46
.
39.
Bange
EM
,
Han
NA
,
Wileyto
P
,
Kim
JY
,
Gouma
S
,
Robinson
J
,
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
.
Nat Med
.
2021
;
27
(
7
):
1280
9
.
40.
Knaus
HA
,
Berglund
S
,
Hackl
H
,
Blackford
AL
,
Zeidner
JF
,
Montiel-Esparza
R
,
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy
.
JCI Insight
.
2018
;
3
(
21
):
e120974
.
41.
Nunes
C
,
Wong
R
,
Mason
M
,
Fegan
C
,
Man
S
,
Pepper
C
.
Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression
.
Clin Cancer Res
.
2012
;
18
(
3
):
678
87
.
42.
Zelle-Rieser
C
,
Thangavadivel
S
,
Biedermann
R
,
Brunner
A
,
Stoitzner
P
,
Willenbacher
E
,
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
.
J Hematol Oncol
.
2016
;
9
(
1
):
116
.
43.
Moderbacher
CR
,
Ramirez
SI
,
Dan
JM
,
Grifoni
A
,
Hastie
KM
,
Weiskopf
D
,
Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
.
Cell
.
2020
;
183
(
4
):
996
1012.e19
.
44.
Shah
GL
,
DeWolf
S
,
Lee
YJ
,
Tamari
R
,
Dahi
PB
,
Lavery
JA
,
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation
.
J Clin Invest
.
2020
;
130
(
12
):
6656
67
.
45.
Sharma
A
,
Bhatt
NS
,
Martin
AS
,
Abid
MB
,
Bloomquist
J
,
Chemaly
RF
,
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
.
Lancet Haematol
.
2021
;
8
(
3
):
e185
93
.
46.
Ljungman
P
,
de la Camara
R
,
Mikulska
M
,
Tridello
G
,
Aguado
B
,
Zahrani
MA
,
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
.
Leukemia
.
2021
;
35
(
10
):
2885
94
.
47.
Busca
A
,
Salmanton-García
J
,
Corradini
P
,
Marchesi
F
,
Cabirta
A
,
Blasi
RD
,
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP
.
Blood Adv
.
2021
:
bloodadvances.2021005616
. Online ahead of print.
48.
Lee
LY
,
Cazier
JB
,
Angelis
V
,
Arnold
R
,
Bisht
V
,
Campton
NA
,
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
.
Lancet
.
2020
;
395
(
10241
):
1919
26
.
49.
Mossuto
S
,
Attardi
E
,
Alesiani
F
,
Angelucci
E
,
Balleari
E
,
Bernardi
M
,
SARS-CoV-2 in myelodysplastic syndromes: a snapshot from early Italian experience
.
Hemasphere
.
2020
;
4
(
5
):
e483
.
50.
Barbui
T
,
Vannucchi
AM
,
Alvarez-Larran
A
,
Iurlo
A
,
Masciulli
A
,
Carobbio
A
,
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
.
Leukemia
.
2021
;
35
(
2
):
485
93
.
51.
Scarfò
L
,
Chatzikonstantinou
T
,
Rigolin
GM
,
Quaresmini
G
,
Motta
M
,
Vitale
C
,
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
.
Leukemia
.
2020
;
34
(
9
):
2354
63
.
52.
Yeleswaram
S
,
Smith
P
,
Burn
T
,
Covington
M
,
Juvekar
A
,
Li
Y
,
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
.
Clin Immunol
.
2020
;
218
:
108517
.
53.
Roschewski
M
,
Lionakis
MS
,
Sharman
JP
,
Roswarski
J
,
Goy
A
,
Monticelli
MA
,
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
.
Sci Immunol
.
2020
;
5
(
48
):
eabd0110
.
54.
Paneesha
S
,
Pratt
G
,
Parry
H
,
Moss
P
.
Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
.
Leuk Res
.
2020
;
93
:
106366
. .
55.
Roeker
LE
,
Eyre
TA
,
Thompson
MC
,
Lamanna
N
,
Coltoff
A
,
Davids
MS
,
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
.
Blood
.
2021
;
138
(
18
):
1768
73
.
56.
Treon
SP
,
Castillo
JJ
,
Skarbnik
AP
,
Soumerai
JD
,
Ghobrial
IM
,
Guerrera
ML
,
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19: infected patients
.
Blood
.
2020
;
135
(
21
):
1912
5
.
57.
Group
RC
,
Horby
P
,
Lim
WS
,
Emberson
JR
,
Mafham
M
,
Bell
JL
,
Dexamethasone in hospitalized patients with Covid-19
.
N Engl J Med
.
2020
;
384
(
8
):
693
704
.
58.
Beigel
JH
,
Tomashek
KM
,
Dodd
LE
,
Mehta
AK
,
Zingman
BS
,
Kalil
AC
,
Remdesivir for the treatment of Covid-19 – final report
.
N Engl J Med
.
2020
;
383
(
19
):
1813
26
.
59.
Abani
O
,
Abbas
A
,
Abbas
F
,
Abbas
M
,
Abbasi
S
,
Abbass
H
,
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
Lancet
.
2021
;
397
(
10285
):
1637
45
.
60.
RECOVERY Collaborative Group
;
Horby
PW
,
Mafham
M
,
Peto
L
,
Campbell
M
,
Pessoa-Amorim
G
,
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
Medrxiv
.
2021
. Epub ahead of print.
61.
Abaleke
E
,
Abbas
M
,
Abbasi
S
,
Abbott
A
,
Abdelaziz
A
,
Abdelbadiee
S
,
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
Lancet
.
2021
;
397
(
10274
):
605
12
.
62.
RECOVERY Collaborative Group
;
Horby
P
,
Mafham
M
,
Linsell
L
,
Bell
JL
,
Staplin
N
,
Effect of hydroxychloroquine in hospitalized patients with Covid-19
.
N Engl J Med
.
2020
;
383
(
21
):
2030
40
.
63.
RECOVERY Collaborative Group
;
Horby
PW
,
Mafham
M
,
Bell
JL
,
Linsell
L
,
Staplin
N
,
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
Lancet
.
2020
;
396
(
10259
):
1345
52
.
64.
Abani
O
,
Abbas
A
,
Abbas
F
,
Abbas
M
,
Abbasi
S
,
Abbass
H
,
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
.
Lancet
.
2021
;
397
(
10289
):
2049
59
.
65.
Simonovich
VA
,
Pratx
LDB
,
Scibona
P
,
Beruto
MV
,
Vallone
MG
,
Vázquez
C
,
A randomized trial of convalescent plasma in covid-19 severe pneumonia
.
N Engl J Med
.
2020
;
384
(
7
):
619
29
.
66.
Korley
FK
,
Durkalski-Mauldin
V
,
Yeatts
SD
,
Schulman
K
,
Davenport
RD
,
Dumont
LJ
,
Early convalescent plasma for high-risk outpatients with covid-19
.
N Engl J Med
.
2021
;
385
(
21
):
1951
60
.
67.
Levy
I
,
Lavi
A
,
Zimran
E
,
Grisariu
S
,
Aumann
S
,
Itchaki
G
,
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
.
Leuk Lymphoma
.
2021
;
62
(
14
):
3384
93
.
68.
US Food and Administration
.
Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19 FDA [Internet]
.
US Food and Administration
;
2021
[cited 2022 Jan 21]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19.
69.
Bernal
AJ
,
Gomes da Silva
MM
,
Musungaie
DB
,
Kovalchuk
E
,
Gonzalez
A
,
Delos Reyes
V
,
Molnupiravir for oral treatment of covid-19 in nonhospitalized patients
.
N Engl J Med
.
2022
;
386
(
6
):
509
20
.
70.
Passamonti
F
,
Romano
A
,
Salvini
M
,
Merli
F
,
Porta
MGD
,
Bruna
R
,
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
.
Br J Haematol
.
2021
;
195
(
3
):
371
7
.
71.
Thompson
MA
,
Henderson
JP
,
Shah
PK
,
Rubinstein
SM
,
Joyner
MJ
,
Choueiri
TK
,
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19
.
JAMA Oncol
.
2021
;
7
(
8
):
1167
75
.
72.
Klassen
SA
,
Senefeld
JW
,
Johnson
PW
,
Carter
RE
,
Wiggins
CC
,
Shoham
S
,
The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis
.
Mayo Clin Proc
.
2021
;
96
(
5
):
1262
75
.
73.
Kloypan
C
,
Saesong
M
,
Sangsuemoon
J
,
Chantharit
P
,
Mongkhon
P
.
Convalescent plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence
.
Eur J Clin Invest
.
2021
;
51
(
11
):
e13663
.
74.
Piechotta
V
,
Iannizzi
C
,
Chai
KL
,
Valk
SJ
,
Kimber
C
,
Dorando
E
,
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
.
Cochrane Database Syst Rev
.
2021
;
5
(
5
):
CD013600
.
75.
Janiaud
P
,
Axfors
C
,
Schmitt
AM
,
Gloy
V
,
Ebrahimi
F
,
Hepprich
M
,
Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19
.
JAMA
.
2021
;
325
(
12
):
1185
95
.
76.
Puing
AG
,
Ho
S
,
Frankel
P
,
Tegtmeier
B
,
Martin
A
,
Ross
J
,
SARS-CoV-2 specific monoclonal antibody for the treatment of mild-to-moderate COVID-19 in cancer patients: a single-center experience
.
J Infect Dis
.
2022
;
225
(
2
):
352
4
.
77.
Razonable
RR
,
Pawlowski
C
,
O’Horo
JC
,
Arndt
LL
,
Arndt
R
,
Bierle
DM
,
Casirivimab: imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
.
EClinicalMedicine
.
2021
;
40
:
101102
.
78.
Le
RQ
,
Li
L
,
Yuan
W
,
Shord
SS
,
Nie
L
,
Habtemariam
BA
,
FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome
.
Oncologist
.
2018
;
23
(
8
):
943
7
.
79.
Hermine
O
,
Mariette
X
,
Tharaux
PL
,
Resche-Rigon
M
,
Porcher
R
,
Ravaud
P
,
Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia
.
JAMA Intern Med
.
2021
;
181
(
1
):
32
40
.
80.
REMAP-CAP Investigators
;
Gordon
AC
,
Mouncey
PR
,
Al-Beidh
F
,
Rowan
KM
,
Nichol
AD
,
Interleukin-6 receptor antagonists in critically ill patients with Covid-19
.
N Engl J Med
.
2021
;
384
(
16
):
1491
502
.
81.
Rosas
IO
,
Bräu
N
,
Waters
M
,
Go
RC
,
Hunter
BD
,
Bhagani
S
,
Tocilizumab in hospitalized patients with severe covid-19 pneumonia
.
N Engl J Med
.
2021
;
384
(
16
):
1503
16
.
82.
Stone
JH
,
Frigault
MJ
,
Serling-Boyd
NJ
,
Fernandes
AD
,
Harvey
L
,
Foulkes
AS
,
Efficacy of tocilizumab in patients hospitalized with covid-19
.
N Engl J Med
.
2020
;
383
(
24
):
2333
44
.
83.
Group TWREA for C-19 T (REACT) W
;
Domingo
P
,
Mur
I
,
Mateo
GM
,
del Gutierrez
MM
,
Pomar
V
,
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19
.
JAMA
.
2021
;
326
(
6
):
499
518
.
84.
Avni
T
,
Leibovici
L
,
Cohen
I
,
Atamna
A
,
Guz
D
,
Paul
M
,
Tocilizumab in the treatment of COVID-19 – a meta-analysis
.
QJM Int J Med
.
2021
;
114
(
8
):
577
86
.
85.
McDonald
I
,
Murray
SM
,
Reynolds
CJ
,
Altmann
DM
,
Boyton
RJ
.
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
.
NPJ Vaccines
.
2021
;
6
(
1
):
74
. .
86.
Griffiths
EA
,
Segal
BH
.
Immune responses to COVID-19 vaccines in patients with cancer: promising results and a note of caution
.
Cancer Cell
.
2021
;
39
(
8
):
1045
7
. .
87.
Greenberger
LM
,
Saltzman
LA
,
Senefeld
JW
,
Johnson
PW
,
DeGennaro
LJ
,
Nichols
GL
.
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
.
Cancer Cell
.
2021
;
39
(
8
):
1031
3
. .
88.
Becerril-Gaitan
A
,
Vaca-Cartagena
BF
,
Ferrigno
AS
,
Mesa-Chavez
F
,
Barrientos-Gutiérrez
T
,
Tagliamento
M
,
Immunogenicity and risk of SARS-CoV-2 infection after COVID-19 vaccination in patients with cancer: a systematic review and meta-analysis
.
Eur J Cancer
.
2022
;
160
:
243
60
.
89.
Herishanu
Y
,
Avivi
I
,
Aharon
A
,
Shefer
G
,
Levi
S
,
Bronstein
Y
,
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
.
Blood
.
2021
;
137
(
23
):
3165
73
.
90.
Greenberger
LM
,
Saltzman
LA
,
Senefeld
JW
,
Johnson
PW
,
DeGennaro
LJ
,
Nichols
GL
.
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
.
Cancer Cell
.
2021
;
39
(
10
):
1297
99
.
91.
Dhakal
B
,
Abedin
S
,
Fenske
T
,
Chhabra
S
,
Ledeboer
N
,
Hari
P
,
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
.
Blood
.
2021
;
138
(
14
):
1278
81
.
92.
Mairhofer
M
,
Kausche
L
,
Kaltenbrunner
S
,
Ghanem
R
,
Stegemann
M
,
Klein
K
,
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
.
Cancer Cell
.
2021
;
39
(
9
):
1171
2
.
93.
Pagano
L
,
Salmanton-García
J
,
Marchesi
F
,
Lopez-Garcia
A
,
Lamure
S
,
Itri
F
,
COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA
.
Blood
.
2021
:
blood.2021014124
. Epub ahead of print.
94.
US Food and Administration
.
Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals FDA [Internet]
.
US Food and Administration
;
2021
[cited 2022 Jan 21]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.